Completed NA INTERVENTIONAL 2-arm NCT03039101

Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

Double Blind Study of Leukotriene Antagonism in the Nasal Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

Sponsor: Mitchell Grayson

Conditions Nasal Allergy

Interventions Epicutaneous skin testing Montelukast 10Mg Tablet Nasal allergen challenge Nasal lavage Peripheral blood Placebo Oral Tablet

Updated 9 times since 2017 Last updated: Oct 3, 2019 Started: Sep 6, 2017 Primary completion: Jul 16, 2018 Completion: Jul 16, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03039101, this NA trial focuses on Nasal Allergy and remains completed. Sponsored by Mitchell Grayson, it has been updated 9 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Nov 2019 — Jan 2021 [monthly]

Completed NA
Aug 2018 — Nov 2019 [monthly]

Completed NA

Status: Active Not Recruiting → Completed

▶ Show 4 earlier versions

Jun 2018 — Aug 2018 [monthly]

Active Not Recruiting NA

Status: Recruiting → Active Not Recruiting
Oct 2017 — Jun 2018 [monthly]

Recruiting NA
Sep 2017 — Oct 2017 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Feb 2017 — Sep 2017 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mitchell Grayson
National Heart, Lung, and Blood Institute (NHLBI)

Data source: Nationwide Children's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Columbus, United States